Mary Caffrey

January 24, 2022

A presentation at the 63rd American Society of Hematology (ASH) annual meeting explored the collection of real-world data.

January 24, 2022

The 63rd American Society of Hematology (ASH) Annual Meeting and Exposition featured leading experts who discussed research on multiple myeloma.

January 24, 2022

Ongoing and new developments in chimeric antigen receptor (CAR) T-cell therapies were covered at the 63rd American Society of Hematology (ASH) annual meeting.

January 24, 2022

Clinical trial results in the leukemia and lymphoma space were covered at the 63rd American Society of Hematology (ASH) annual meeting.

January 24, 2022

January 24, 2022

Disparities and inequities in care were topics of interest at the 63rd American Society of Hematology (ASH) annual meeting.

January 20, 2022

Zanubrutinib is a second-generation Bruton tyrosine kinase (BTK) inhibitor that has fewer off-target effects and less cardiotoxicity than ibrutinib, a first-generation BTK inhibitor.

January 18, 2022

There has not been a change in the standard of care in this type of cancer in a decade, according to an expert from ASCO.

January 18, 2022

Merck had previously received accelerated approval for pembrolizumab for patients with advanced hepatocellular carcinoma (HCC); an FDA panel left the approval in place while waiting on results from KEYNOTE-394.

January 18, 2022

Stephen Schleicher, MD, MBA, and Natalie Dickson, MD, discuss their new roles as chief medical officer (CMO) and chief strategy officer (CSO), respectively, at Tennessee Oncology.